Scientific Program of LAA 2014
|
|
|
- Hollie Weaver
- 5 years ago
- Views:
Transcription
1 Scientific Program of LAA 2014 Friday, November 14th, :00-18:30 Registration 08:00-08:05 Welcome 08:05-08:45 Session 1: How Morphology Affects Short- and Long-term Outcome? What you Need to Know Moderator: Neil Wilson, MD / Stefan Bertog, MD / Julie Humphries, MD The Pathologist Point of View: Demonstration of a Heart Dissection Yen Ho, MD Implications for the Implanter Maxim Didenko, MD 08:45-10:15 Session 2: LAA Imaging Moderator: Shakeel A. Qureshi, MD / Sameer Gafoor, MD / Maurice Buchbinder, MD Screening and Intra-procedural TEE: Basics and Advanced Tips and Tricks Julie Humphries, MD Intraprocedural Angiography 3D Rotational Angiography Tom de Potter, MD TEE Follow-up: Thrombus and Residual Leak Simon Lam, MD ICE Guidance During LAA Closure Sergio Berti CT: Using Osirix Sergio Berti 09:00-18:00 AMPLATZER Left Atrial Appendage Occlusion Virtual Reality Training 09:00-18:00 WATCHMANTM Implant Simulation Based in Simbionix Virtual Reality 09:00-18:00 WATCHMANTM Trans-esophageal Echo Simulation Based in IML Heartworks Virtual Reality 09:00-15:00 CT Training for LAA Closure 09:00-15:00 LARIAT Procedure Bench TopTraining 09:00-10:00 Parallel: How to Retrieve Embolized Devices 10:15-10:45 Coffee & Tea Break 10:45-12:45 Session 3: LAA Closure With the Watchman Occluder - LAA Closure: What have we learned and where do we go? Moderator: Neil Wilson, MD / Gilles. Montalescot, MD Scientific Update and Data From Daily Practice Lucas Boersma, MD Which Anti-thrombotic strategy for which patient?
2 Specific Design Features of the Watchman Device: Major Differences to Other Devices Watchman Step by Step TEE Follow-up After Watchman Implantation Julie Humphries, MD Patient Identification-Creating of a Successful LAA Closure Practice Two Examples From Real Life - The Interventionalist ś Point of View Richard Folkeringa, MD Two Examples From Real Life - The Neurologist ś Point of View 11:00-12:00 Human and Animal Specimens 12:45-13:45 Lunch Break and Industry Exhibition 13:45-15:45 Sesion 4: LAA Occlusion With Amplatzer LAA Devices Moderator: Apostolos Tzikas, MD / Fabian Nietlispach, MD Specific Design Features of the Amplatzer Device: Major Differences to Other Devices Dabit Arzamendi, MD AMPLATZER LAA Devices: Step-by-Step Jens Erik Nielsen - Kudsk, MD TEE of the LAA Prior, During and After LAA Closure With the Amplatzer Occluder Klaus Tiemann, MD Building My LAA Practice Johannes Brachmann, MD Fabian Nietlispach, MD 14:00-15:00 Advanced Watchman Seminar - Talk to the Proctors 15:45-16:00 Coffee & Tea Break 16:00-17:30 Session 5: How to Close the LAA With the Lariat Device Moderator: Shakeel A. Qureshi, MD / Randall (Randy) Lee, MD How to Select Patients for the Lariat Device Pericardial Access for LAA Closure - The Mystery and the Reality Lariat Step by Step Randall (Randy) Lee, MD LARIAT Experience in Patients Contraindicated to Anticoagulation Sameer Gafoor, MD Ligation and Ablation Versus Ablation Only in Patients With Persistent AF
3 Post Procedure Management with LARIAT Hosakote Nagaraj, MD Krzysztof Bartus, MD Treatment Strategies in Patients With Incomplete Closure of the LAA Gafoor Sameer 16:00-17:00 Advanced ACP Seminar - Talk to the Proctors 17:30-18:30 Advanced Lariat Seminar - Talk to the Proctors 17:30-18:30 Session 6: LAA Closure With the Coherex WaveCrest Occluder Moderator: Neil Wilson, MD / Specific Design Features of the WaveCrest LAA Occlusion System Brian Whisenant, MD WaveCrest Step by Step Tom de Potter, MD KR Julian Chun, MD back to top Saturday, November 15th, :30-18:00 Registration 08:00-10:00 Session 7: Rationale for LAA Closure Moderator: Shakeel A. Qureshi, MD / Stefan Bertog, MD Pharmacological Stroke Prevention in Atrial Fibrillation - What are the Main Concerns Heyder Omran When Does LAA Exclusion Make Sense? The Clinical Need, Risks and Benefits Antithrombotic Treatment After LAA Closure MitraClip and TAVI Combined With LAA Closure Fabian Nietlispach, MD Debate Atrial Fibrillation Ablation and LAA Closure Should be Performed During the Same Session LAA Closure Should not be Performed During the Same Session Randall (Randy) Lee, MD Impact of LAA Exclusion on Cardiovascular Physiology and Systemic Homeostasis 09:00-18:00 AMPLATZER Left Atrial Appendage Occlusion Virtual Reality Training 09:00-18:00 WATCHMAN Implant Simulation Based in Simbionix Virtual Reality 09:00-18:00 WATCHMANTM Trans-esophageal Echo Simulation Based in IML Heartworks Virtual Reality 09:00-15:00 CT Traning for LAA Closure
4 09:00-15:00 LARIAT Procedure Bench Top Training 09:00-10:00 Parallel: How to Retrieve Embolized Devices 10:00-10:30 Coffee & Tea Break 10:30-12:30 Session 8: LAA Closure: A Multidisciplinary Approach Moderator: Neil Wilson, MD / What to Consider Before you Start Your Program Health Care Economics of LAA Closure Sandeep Panikker, MD 12:30-13:15 Lunch Break and Industry Exhibition 13:15-14:15 Session 9: Update on Clinical Trial Results Moderator: Shakeel A. Qureshi, MD / Stefan Bertog, MD / Martin W. Bergmann Watchman Stefan Bertog, MD Amplatzer Apostolos Tzikas, MD Lariat WaveCrest New Guidelines and Recommendations 14:15-15:30 Session 10: New Devices and Techniques Moderator: Neil Wilson, MD / Stefan Bertog, MD / Sameer Gafoor, MD The Amplatzer Amulet Kevin P. Walsh, MD Lifetech LAA Closure Device: Initial Human Experience Yat-Yin Lam, MD Initial Results of the Clinical Trial With Occlutech LAA Occluder Recorded Live Case: Occlutech LAA Occluder Initial Results with the PROLIPSIS device Basilios Sideris AtriClip / Mark La Meir, MD How to Close Residual Leaks Sameer Gafoor, MD 15:30-16:00 Coffee & Tea Break 16:00-18:00 Session 11: Challenging Cases and Complications Moderator: Shakeel A. Qureshi, MD / Neil Wilson, MD Case 1: Delayed Onset of Pericarditis After Percutaneous Device Closure of Left Atrial Appendage Yong-Giun Kim, MD Case 2: Very Large LAA Case 3: Air Embolism During Left Atrial Appendage Occlusion
5 Lee Hyun Jong, MD
Hands on workshops. 08:00-10:15 Session 1 - LAA morphology and imaging Moderator: Saibal Kar, MD / Shakeel A. Qureshi, MD / Bushra Rana, MD
Friday, November 20th, 2015 07:00-18:30 Registration 07:00-08:00 Welcome coffee Hands on workshops 08:00-10:15 Session 1 - LAA morphology and imaging Moderator: Saibal Kar, MD / Shakeel A. Qureshi, MD
Scientific Program of CSI Focus Imaging 2017
Scientific Program of CSI Focus Imaging 2017 Wednesday, June 28th, 2017 07:00-08:00 Registration and breakfast in the exhibition area 08:00-08:05 Welcome and introduction Moderator: Horst Sievert, MD /
Modern aspects in multidisciplinary thromboembolic prophylaxis. AMPLATZER Left Atrial Appendage data update
Modern aspects in multidisciplinary thromboembolic prophylaxis AMPLATZER Left Atrial Appendage data update Igal Moarof, MD Interventional Cardiology Kantonsspital Aarau Potential conflicts of interest
SURGICAL VS ELECTROPHYSIOLOGICAL INTERVENTIONS FOR CARDIAC ARRHYTHMIAS DEBATE 2: LAA CLOSURE IS BEST DONE WITH DEVICES
SURGICAL VS ELECTROPHYSIOLOGICAL INTERVENTIONS FOR CARDIAC ARRHYTHMIAS DEBATE 2: LAA CLOSURE IS BEST DONE WITH DEVICES Dr. Marco Barbierato Interventional Cardiology Cardio-Thoraco-Vascular Department
Percutaneous Epicardial LAA Closure: When Does it Make Sense?
Percutaneous Epicardial LAA Closure: When Does it Make Sense? Petr Neuzil, MD,PhD, FESC Professor of Medicine Cardiology department Na Homolce Hospital, Prague, Czechia petr.neuzil@gmail.com Disclosures
Devices to Protect Against Stroke in Atrial Fibrillation
Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria
Clinical Data Summary & Discussion Of the Ultraseal Left Atrial Appendage (LAA) Closure Device
Clinical Data Summary & Discussion Of the Ultraseal Left Atrial Appendage (LAA) Closure Device The clinical data used to support the CE marking of the Ultraseal LAA Closure device comes from three sources.
3 rd BELGIAN LEFT ATRIAL APPENDAGE OCCLUSION MEETING. Friday Hotel Dolce La Hulpe Brussels
3 rd BELGIAN LEFT ATRIAL APPENDAGE OCCLUSION MEETING Friday 23.11.2018 Hotel Dolce La Hulpe Brussels MEETING OBJECTIVES Dear Colleagues, Oral anticoagulation remains the mainstay of therapy for stroke
David Hildick-Smith, John Camm, Hans-Christoph Diener, Ulf Landmesser, Vincent Paul, Boris Schmidt, Magnus Settergren, Emmanuel Teiger, Claudio Tondo
THE AMULET STUDY: A Multicenter, Prospective Registry of the Amulet Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial Fibrillation David Hildick-Smith, John Camm, Hans-Christoph
Role of cardiac imaging for catheterbased left atrial appendage closure
Role of cardiac imaging for catheterbased left atrial appendage closure Ana G. Almeida, MD, PhD Cardiology University Hospital Santa Maria, Lisbon Ana G. Almeida, MD, PhD, FESC University Hospital Santa
Left atrial appendage occlusion
Kardiologie Left atrial appendage occlusion Mischa Kühne Kardiolunch, 10.9.2015 Overall stroke rate 5% per year CHA 2 DS 2 VASC score Most AF patients need protection from stroke ESC guidelines AF, 2010/2012
LAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC
LAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC INTERVENTIONAL CARDIOLOGIST DIRECTOR, ADULT CARDIOLOGY FELLOWSHIP TRAINING
Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016
Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016 Jesse Jorgensen, MD, FACC Director, Cardiac Cath Lab, Greenville Health System Disclosures
Medical Policy Manual. Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation. Date of Origin: December 2011
Medical Policy Manual Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Date of Origin: December 2011 Section: Medicine Last Reviewed Date: October 2013 Policy No:
Left Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE
Left Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE Adam Greenbaum, MD NCVH Detroit 2015-09-12 Disclosures Former proctor: SentreHEART Discussion may include the use of non-fda approved devices
Atrial fibrillation (AF) remains the most common
The Spectrum of Devices for Percutaneous Left Atrial Appendage Occlusion A look at current and emerging nonpharmacologic stroke prevention therapies. BY LLUIS ASMARATS, MD, AND JOSEP RODÉS-CABAU, MD Atrial
Left Atrial Appendage Closure: The Good, The Bad and The Ugly
Left Atrial Appendage Closure: The Good, The Bad and The Ugly John D. Hummel, MD Director of Electrophysiology Research Ross Heart Hospital, The Ohio State University Columbus, Ohio USA Disclosures Modest
Left Atrial Appendage Closure Devices. Atrial Fibrillation 10/11/2017
Left Atrial Appendage Closure Devices Emile Daoud, MD Chief, Cardiac Electrophysiology Wexner Medical Center, The Ohio State University Atrial Fibrillation 1 Adjusted Annual Stroke Risk Using CHA 2 DS
Update in Left Atrial Appendage Closure Devices. Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS
Update in Left Atrial Appendage Closure Devices Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS Atrial Fibrillation - Overview Higher stroke risk for older patients and those with prior stroke or
NHS England. Anticoagulation Therapy
NHS England Evidence review: Clinical and Cost- Effectiveness and Adverse Events Associated with Left Atrial Appendage Occlusion in Patients for Whom Anticoagulation Therapy is Contraindicated Anticoagulation
Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Medical Policy Manual Surgery, Policy No. 195 Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Next Review: November 2019 Last Review: January 2019 Effective: February
Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD
Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD Director of Interventional Cardiac Research Cedars Sinai Medical Center Disclosure Statement
Left atrial appendage closure with the Amplatzer Cardiac Plug: Rationale for a higher degree of device oversizing at implantation
ORIGINAL ARTICLE Cardiology Journal 2015, Vol. 22, No. 2, 201 205 DOI: 10.5603/CJ.a2014.0063 Copyright 2015 Via Medica ISSN 1897 5593 Left atrial appendage closure with the Amplatzer Cardiac Plug: Rationale
Which System Is better?: Watchman or Cardiac Plug or Something Else?
ANGIOPLASTY SUMMIT-TCTAP 2012 Seoul, Korea, April 24-27, 2012 Which System Is better?: Watchman or Cardiac Plug or Something Else? Horst Sievert, Annkathrin Brauth, Isabel Schulmeyer, Patrick Boehm, Jonas
Case Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device
273 Case Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device Amena Hussain MD, Muhamed Saric MD, Scott Bernstein MD, Douglas Holmes MD, Larry Chinitz MD NYU Langone Medical Center, United
Appendage Closure. Jason Rogers, MD. Director, Interventional Cardiology UC Davis Medical Center Sacramento, California
Appendage Closure Jason Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Sacramento, California Left Atrium: Atrial Fibrillation Left Atrial Appendage Left Atrium Incidence of Atrial
Left Atrial Appendage Closure in SCRIPPS CLINIC
Left Atrial Appendage Closure in Atrial Fibrillation to Prevent Stroke Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org
Clinical Policy Bulletin: Cardiac Devices and Procedures for Occlusion of the Left Atrial Appendage
Close Window Enter CPB Search Term: Go Clinical Policy Bulletin: Cardiac Devices and Procedures for Occlusion of the Left Atrial Appendage Number: 0791 Policy *Please see amendment for Pennsylvania Medicaid
Disclosures 6/16/2015. Preventing Stroke in Atrial Fibrillation Warfarin Intolerance / Non-Compliance
6/16/2015 Data Behind LAA Closure This is Ready for Prime Time! Vivek Y. Reddy, MD Helmsley Trust Professor of Medicine Director, Cardiac Arrhythmia Service The Mount Sinai Hospital vivek.reddy@mountsinai.org
Europe. Other LAA occlusion devices are in clinical development.
EXPERT REVIEW INTERVENTIONS FOR STRUCTURAL HEART DISEASE Left atrial appendage closure for stroke prevention in nonvalvular atrial fibrillation: rationale, devices in clinical development and insights
Trick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT?
Trick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT? Disclosure SentreHeart, Inc Consultant Equity holder A cardiac disease that kills by producing emboli The most severe consequence
ICE 2012 Ioannina,
ICE 2012 Ioannina, 15-12-2012 Case presentation Left Atrial Appendage Occlusion therapy for Stroke Prevention in Atrial Fibrillation Apostolos Tzikas MD, PhD, FESC Interventional Cardiology Congenital
Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation
Received: 15 May 2017 Revised: 21 June 2017 Accepted: 26 June 2017 DOI: 10.1002/clc.22764 REVIEWS Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation Rizma Jalees
[N] = No product variation, policy applies as stated [Y] = Standard product coverage varies from application of this policy, see below
![[N] = No product variation, policy applies as stated [Y] = Standard product coverage varies from application of this policy, see below](/thumbs/89/100529598.jpg "[N] = No product variation, policy applies as stated [Y] = Standard product coverage varies from application of this policy, see below")
Original Issue Date (Created): July 26, 2011 Most Recent Review Date (Revised): November 26, 2013 Effective Date: February 1, 2014 I. POLICY The use of percutaneous left-atrial appendage closure devices
Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute ischemic stroke TOAST classification of, 270 Acute myocardial infarction (AMI) cardioembolic stroke following, 207 208 noncardioembolic
MEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES EFFECTIVE DATE: 08/20/15 REVISED DATE: 10/20/16, 11/16/17
MEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL CATEGORY: Technology assessment PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.
MEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT POLICY GUIDELINES DESCRIPTION. Page: 1 of 9
Page: 1 of 9 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES Policy Number 7.01.92 Category Technology assessment Effective Date 08/20/15 Revised
Role of Imaging in Complex LAA Closure Anatomies
Role of Imaging in Complex LAA Closure Anatomies Sameer Gafoor 1,2 1 Swedish Heart and Vascular: Ming Zhang, Paul Huang, Darryl Wells, Adam Zivin, John Petersen II, Madalena Petrescu, Nimish Muni, Eric
Thessaloniki October 9, Apostolos Tzikas MD, PhD, FESC
7 th IICE Congress Thessaloniki October 9, 2014 Left atrial appendage occlusion with the Amplatzer Amulet: a case report Apostolos Tzikas MD, PhD, FESC Interventional Cardiologist Structural & Congenital
Left atrial appendage closure: outcomes and challenges
Neth Heart J (2017) 25:143 151 DOI 10.1007/s12471-016-0929-0 REVIEW ARTICLE Left atrial appendage closure: outcomes and challenges H. S. Suradi 1,2,3 Z.M.Hijazi 4 Published online: 9 December 2016 The
Cryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
Continuing Cardiology Education
Continuing Cardiology Education REVIEW ARTICLE Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: indications diversity and future perspectives A. Tzikas 1 & T.
Recurrent Stroke under Anticoagulation in Mild MS & AF
Recurrent Stroke under Anticoagulation in Mild MS & AF - Minimal maze operation and LAA excision or exclusion- Seung Hyun Lee, M.D, Ph.D Division of Thoracic and Cardiovascular surgery Severance cardiovascular
ATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE ECHOCARDIOGRAPHY IN INTERVENTIONAL CARDIOLOGY
ATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE Aristides G. Panlilio, MD, FPCP, FPCC,FPSE, FASE Philippine Heart Center Chinese General Hospital and Medical Center
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Percutaneous Left Atrial Appendage Closure Device Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Percutaneous Left Atrial Appendage Closure Devices
PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES
PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES Dr.Vinny K.Ram No disclosures TAVR 1 Lesson number 1:
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Policy Number: 2.02.26 Last Review: 6/2014 Origination: 1/2012 Next Review: 12/2014 Policy Blue Cross and
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation Zoltan G. Turi, M.D. Rutgers Robert Wood Johnson Medical School New Brunswick, NJ Disclosure Information Zoltan G.
NCVH Birmingham 2013 August 24, Michael S. Bailey, MD Birmingham Heart Clinic
NCVH Birmingham 2013 August 24, 2013 Michael S. Bailey, MD Birmingham Heart Clinic NCVH Birmingham 2015 August 29, 2015 Michael S. Bailey, MD Birmingham Heart Clinic Left Atrial Anatomy Part of a larger
Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC
Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion Greg Francisco, MD, FACC DISCLOSURES None to declare Estimated 33.5million have AF worldwide (6-7million in
Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives
Review Article Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives Bin Kong 1,2, Yu Liu 1,2, He Huang 1,2, Hong Jiang 1,2, Congxin
LAmbre LAA Occluder Updates
LAmbre LAA Occluder Updates 4 th Asia Pacific Congenital & Structural Interventional Symposium 6 th June, 2013 Hong Kong Yat-yin LAM MBBS MRCP FHKCP FHKAM FESC FRCP FACC MD Associate Professor, Prince
Exclusion de l auricule gauche par voie percutanée
Exclusion de l auricule gauche par voie percutanée Jean-Michel Juliard, Dominique Himbert, Pierre Aubry, Eric Brochet, Alec Vahanian Hôpital Bichat, Paris Pas de conflit d intérêt 2012 The Left Atrial
16th ANGIOPLASTY SUMMIT-TCTAP TCTAP 2011 Seoul, Korea, April 27 29, 2011 Left Atrial Appendage Closure State of the Art Horst Sievert, Nina Wunderlich, Maik Gonzaga, Annkathrin Braut, Ilona Hofmann CardioVascular
Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Section Medicine
2.02.26 Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Section Medicine Effective Date August 29, 2014 Subsection Cardiology Original Policy Date July 6,
Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
Joint Congress PAFCIC Complex PCI meeting
Joint Congress PAFCIC Complex PCI meeting October 18-20, 2018, Nairobi, KENYA The Program : - Interactive sessions - Practical workshops - Key note lectures - Live transmissions - Poster and oral presentations
Atrial fibrillation (AF), one of the
Hellenic J Cardiol 2013; 54: 408-412 Case Report Left Atrial Appendage Occlusion with the Amplatzer Amulet for Stroke Prevention in Atrial Fibrillation: The First Case in Greece Apostolos Tzikas, Lambros
Patients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Heart Institute, Cedars-Sinai Medical Center,
TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations
TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations DATE: 29 September 2010 CONTEXT AND POLICY ISSUES: Atrial fibrillation (AF) is the irregular, rapid beating of the
Review Article Thromboembolism Prevention via Transcatheter Left Atrial Appendage Closure with Transeosophageal Echocardiography Guidance
Hindawi Publishing Corporation rombosis Volume 2014, Article ID 832752, 6 pages http://dx.doi.org/10.1155/2014/832752 Review Article Thromboembolism Prevention via Transcatheter Left Atrial Appendage Closure
Pathology of Atrial Septal Defects. To Close or not to Close?: Atrial Septal Defects are NOT That Simple-Sometimes
Scientific Program Thursday, June 7, 2007 09:00 19:00 Registration 09:00 10:00 Breakfast at the Congress Center 10:00 10:05 Opening Remarks H. Sievert 10:05 10:15 Follow-up of the Patients 2006 C. Heinisch
Abstract 1 INTRODUCTION ORIGINAL ARTICLE
Received: 5 October 2017 Revised: 2 November 2017 Accepted: 6 November 2017 DOI: 10.1111/jce.13385 ORIGINAL ARTICLE Feasibility of percutaneous left atrial appendage closure using a novel LAmbre occluder
Introduction EP WIRE. ... Keywords
Europace (217), 1 6 doi:1.3/europace/eux254 EP WIRE Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association
RESPECT Safety Findings
CO-1 SCAI Town Hall Meeting Monday, October 31, 2016 Washington, DC RESPECT Safety Findings John D. Carroll, M.D., MSCAI Professor of Medicine Cardiology University of Colorado School of Medicine University
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Policy Number: 2.02.26 Last Review: 12/2018 Origination: 1/2012 Next Review: 12/2019 Policy Blue Cross and
Filling the gap: interventional occlusion of incompletely ligated left atrial appendages
Europace (2015) 17, 64 68 doi:10.1093/europace/euu164 CLINICAL RESEARCH Ablation for atrial fibrillation Filling the gap: interventional occlusion of incompletely ligated left atrial appendages Stefano
Technique, Risk, and Benefit. T. Santoso University of Indonesia Medical School,
Left Atrial Appendage Closure Technique, Risk, and Benefit T. Santoso University of Indonesia Medical School, Medistra Hospital, Jakarta, Indonesia Percutaneous LAA Closure Devices PLAATO (no longerdeveloped)
CSI Asia-Pacific March 5-7, 2015 Ho Chi Minh City, Vietnam Programme as of Jan 15, 2015
Thursday, March 5, 2015 7:00-19:00 Registration 7:55-8:00 Welcome and Introduction Course Directors 8:00-9:30 Session 1 Atrial Septal Defects Moderators: Worakan Promphan, Pham Gia Khai, Shakeel Qureshi
PERCUTANEOUS LEFT ATRIAL APPENDAGE OCCLUSION FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION:
PERCUTANEOUS LEFT ATRIAL APPENDAGE OCCLUSION FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION: Procedural Experience and Clinical Follow-up with the AMPLATZER Cardiac Plug and AMPLATZER Amulet
Watchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg
Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure
Five years of keeping a watch on the left atrial appendage how has the WATCHMAN fared?
Perspective Five years of keeping a watch on the left atrial appendage how has the WATCHMAN fared? Mohammad-Ali Jazayeri, Venkat Vuddanda, Valay Parikh, Madhav Lavu, Donita Atkins, Y. Madhu Reddy, Jayant
Commercial Products Percutaneous left atrial appendage closure is considered medically necessary when the criteria above is met.
Medical Coverage Policy Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation EFFECTIVE DATE: 07 01 2016 POLICY LAST UPDATED: 09 04 2018 OVERVIEW Stroke prevention
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Last Review Status/Date: December 2015 Page: 1 of 17 Devices for Stroke Prevention in Atrial Description Stroke prevention in atrial fibrillation is an important consideration. Treatment with anticoagulant
Gauging stroke risk across the AF spectrum and selecting the appropriate patient for LAA closure. Miguel Valderrábano, MD
Gauging stroke risk across the AF spectrum and selecting the appropriate patient for LAA closure Miguel Valderrábano, MD Risk of Stroke in Atrial Fibrillation CHADS 2 -CHA 2 DS 2 -VASc Scores Adjusted
Together. INFINITE POSSIBILITIES.
ST. JUDE MEDICAL IS NOW ABBOTT Together. INFINITE POSSIBILITIES. Abbott and St. Jude Medical have joined together. Visit us at EuroPCR 2017. Join us at our exciting scientific sessions, and explore our
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
Dad needed to get off his blood thinner. His doctor told us about an alternative. It s called
Dad needed to get off his blood thinner. His doctor told us about an alternative. It s called A one-time procedure that may reduce stroke risk for a lifetime in people with AFib not caused by a heart valve
Safety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup
Safety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup Martin W. Bergmann, Hüseyin Ince, Stephan Kische, Thomas Schmitz, Felix Meincke, Boris Schmidt, David Foley, Timothy
A PATIENT S GUIDE TO THE LEFT ATRIAL APPENDAGE CLOSURE. Reducing the risk of stroke in atrial fibrillation
A PATIENT S GUIDE TO THE LEFT ATRIAL APPENDAGE CLOSURE Reducing the risk of stroke in atrial fibrillation TABLE OF CONTENTS IMPORTANT Please Note: Information provided by Boston Scientific Corporation
Cardiac Imaging in abnormal rhythm Role of MDCT
Cardiac Imaging in abnormal rhythm Role of MDCT Cardiac Imaging in abnormal rhythm Role of MDCT Scope of the problem CT in Atrial Fibrillation CT and pacing Ventricular arrhythmia Other applications 1
The evolving role of left atrial appendage occlusion
ORIGINAL ARTICLE 288 A high-volume single-centre experience The evolving role of left atrial appendage occlusion Raffael A. Ghenzi, Slayman Obeid, Francesco Maisano, Maurizio Taramasso, Ronald Binder,
Percutaneous Left Atrial Appendage Closure - Ready for prime time?
Percutaneous Left Atrial Appendage Closure - Ready for prime time? Simone Musco, MD, FACC, FHRS The International Heart Institute of Montana ACP Montana chapter meeting September 28th 2017 Simone.Musco@providence.org
Program Schedule Cardiology Update in Sedona: The Heart of the Matter
Thursday, August 3, 2017 Program Schedule Cardiology Update in Sedona: The Heart of the Matter Noon Registration and Exhibits 1:50 p.m. Welcome Announcements SESSION 1 MODERATORS: Luis R. Scott, M.D and
Left Atrial Appendage Closure: Techniques and Guidelines. Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA
Left Atrial Appendage Closure: Techniques and Guidelines Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA May is Stroke Awareness Month 2 September is AF Awareness Month Lecture Highlights
Update in Left Atrial Appendage Occlusion: More Options
Update in Left Atrial Appendage Occlusion: More Options Sajjad A Sabir, MD Director, Structural Heart Disease Program Director, Interventional Echocardiography Director, Heart Valve Clinic Non-Valvular
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
Case Report Pulmonary Vein Compression After Implantation of a Left Atrial Appendage Occluder: Presentation and Discussion of a Case
194 Case Report Pulmonary Vein Compression After Implantation of a Left Atrial Appendage Occluder: Presentation and Discussion of a Case Maryam Ayati MD, Feifan Ouyang MD, KH Kuck MD Department of cardiology,
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion
Europace (2014) 16, 1397 1416 doi:10.1093/europace/euu174 EHRA/EAPCI CONSENSUS STATEMENT EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion Bernhard Meier (EAPCI Chairperson)
Index. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Alagille syndrome, pulmonary artery stenosis in, 143 145, 148 149 Amplatz devices for atrial septal defect closure, 42 46 for coronary
Reference: NHS England 1692
Clinical Commissioning Policy Proposition: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (Adults) Reference: NHS England
12:00-13:00 Training room GE Healthcare-Boston Scientific Training Village Interventions for Valvular Disease TAVI Focus on Imaging
Program Tuesday 16 May 2017 12:00-13:00 Training room GE Healthcare-Boston Scientific Interventions for Valvular Disease TAVI Experience virtual reality and sizing for TAVI Physician Trainer: L. Ihlberg
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
Core Curriculum for the Cardiovascular Clinician
September 14 17, 2016 Heart House Washington, DC AGENDA Wednesday, September 14 PHARMACOLOGY WORKSHOP 5:30 p.m. Registration and Light Refreshments 6:00 p.m. Welcome and Introductions 6:15 p.m. CVD Guideline-driven
NHS England Reference: P
Clinical Commissioning Policy: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (adults) NHS England Reference: 170060P
Rate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A AADs. See Antiarrhythmic drugs (AADs) ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors ACP in transseptal approach to
Percutane structurele interventies. Hartoor sluiting (Watchman )
Percutane structurele interventies Dr. Luc Muyldermans Dr. Yves Vandekerckhove Dr. Luc Missault Dr. Daniël Dendooven Dr. Patrick Coussement Prof. Mattias Duytschaever Prof. René Tavernier Dr. Philippe
Protocol. Always. Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Always Protocol Percutaneous Left Atrial Appendage Closure Devices for Stroke (20226) Medical Benefit Effective Date: 07/01/16 Next Review Date: 03/19 Preauthorization Yes Review Dates: 11/15, 03/16, 03/17,